Number of participants with pain due to IAD · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with pain due to skin care product or procedure · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic reaction · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incremental cost‐effectiveness · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women who reported pain on Visual Analogue Scale · pregnant women with, or at risk of developing, pelvic and back pain
Pelvic + low‐back pain: any exercises + usual prenatal care probably leads to lower number of women who reported pain on Visual Analogue Scale. compared with usual prenatal care (moderate certainty).
1 finding from 1 review
Number of women who reported LBPP‐related sick leave. · pregnant women with, or at risk of developing, pelvic and back pain
Pelvic + low‐back pain: any exercises + usual prenatal care probably leads to lower number of women who reported LBPP‐related sick leave. compared with usual prenatal care (moderate certainty).
1 finding from 1 review
Quality of life · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
The review found no eligible studies for this question.
1 finding from 1 review
Toxicity / adverse effects (harms) of chemotherapy · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Patient perceived satisfaction (denture preference) · Participants with an atrophic maxilla who cannot be rehabilitated with conventional dental implants due to lack of bone (including…
The review found no eligible studies for this question.
1 finding from 1 review
Complications · Participants with an atrophic maxilla who cannot be rehabilitated with conventional dental implants due to lack of bone (including…
The review found no eligible studies for this question.
1 finding from 1 review
Prosthesis failure · Participants with an atrophic maxilla who cannot be rehabilitated with conventional dental implants due to lack of bone (including…
The review found no eligible studies for this question.
1 finding from 1 review
Cost‐effectiveness · Participants with an atrophic maxilla who cannot be rehabilitated with conventional dental implants due to lack of bone (including…
The review found no eligible studies for this question.
1 finding from 1 review
Implant failure rate · Participants with an atrophic maxilla who cannot be rehabilitated with conventional dental implants due to lack of bone (including…
The review found no eligible studies for this question.
1 finding from 1 review
1‐year‐survival · adult patients after liver transplantation.
It is very uncertain whether parenteral nutrition with alanyl‐glutamine, protein, fat,… changes 1‐year‐survival compared with 5% dextrose and normal saline (very low certainty).
1 finding from 1 review
3‐year‐survival · adult patients after liver transplantation.
It is very uncertain whether parenteral nutrition with alanyl‐glutamine, protein, fat,… changes 3‐year‐survival compared with 5% dextrose and normal saline (very low certainty).
1 finding from 1 review
Confirmed SARS‐CoV‐2 infection · school staff
It is very uncertain whether test‐based attendance changes rates of any PCR‐positive SARS‐CoV‐2 infection (over 13‐week compared with routine isolation after contact with a SARS‐CoV‐2‐positive person (very low certainty).
1 finding from 1 review
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review